Alaunos Therapeutics (NASDAQ:TCRT) Issues Quarterly Earnings Results

Alaunos Therapeutics (NASDAQ:TCRT) released its earnings results on Tuesday. The company reported ($0.36) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.00 million during the quarter.

Alaunos Therapeutics Trading Up 3.1%

Shares of Alaunos Therapeutics stock opened at $2.95 on Thursday. The firm has a market capitalization of $6.84 million, a PE ratio of -1.33 and a beta of -1.13. The firm’s 50 day moving average is $2.96 and its 200 day moving average is $3.06. Alaunos Therapeutics has a 1 year low of $1.67 and a 1 year high of $6.20.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently raised its stake in Alaunos Therapeutics stock. Geode Capital Management LLC grew its stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,736 shares of the company’s stock after buying an additional 3,945 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of Alaunos Therapeutics worth $64,000 as of its most recent SEC filing. 27.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Alaunos Therapeutics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.